Anthem clinical criteria updates for specialty pharmacy are available
Access the clinical criteria document information.
Anthem’s prior authorization clinical review of non-oncology specialty pharmacy drugs will be managed by Anthem’s medical specialty drug review team. Drugs used for the treatment of Oncology will be managed by AIM Specialty Health® (AIM), a separate company
- ING-CC-0130 Imfinzi (durvalumab)
- ING-CC-0145 Libtayo (cemiplimab-rwlc)
- ING-CC-0159 Scenesse (afamelanotide)
- ING-CC-0193 Evkeeza (evinacumab)
June 2021 Anthem Provider News - Georgia